Top

Published in:

01-03-2008 | Epidemiology

Genetic variation of TP53, polycyclic aromatic hydrocarbon-related exposures, and breast cancer risk among women on Long Island, New York

Authors: Mia M. Gaudet, Marilie D. Gammon, Jeannette T. Bensen, Sharon K. Sagiv, Sumitra Shantakumar, Susan L. Teitelbaum, Sybil M. Eng, Alfred I. Neugut, Regina M. Santella

Published in: Breast Cancer Research and Treatment | Issue 1/2008

Abstract

Background

p53 participates in cell cycle control, programmed cell death/apoptosis, and DNA repair, all pathways involved in carcinogenesis. TP53 variants may influence p53 function.

Objectives

We evaluated whether three well-characterized TP53 variants—Ex4 + 119 C > G (rs#1042522, Arg72Pro), IVS6 + 62 A > G (rs#1625895), and an IVS3 16 bp insertion/ deletion (INDEL; rs#17878362)—were associated with breast cancer risk in a population-based case-control study.

Methods

Genotypes and haplotypes were determined using long-range PCR in a sample of 578 cases and 390 controls.

Results

For the Ex4 + 19 C > G SNP (rs1042522), women with the heterozygous genotype (G/C) had a 32% increase in breast cancer risk. Other variants were not associated with risk. We further examined whether these associations were modified by cigarette smoking status and detection of PAH–DNA adducts in circulating lymphocytes. Among current smokers, each copy of the minor alleles for the IVS6 + 62 A > G SNP (rs1625895) and the IVS3 INDEL polymorphism (rs17878362) was associated with lower breast cancer risk (OR = 0.49, 95% CI 0.27–0.90; OR = 0.42, 95% CI 0.22–0.78, respectively). However, among former smokers, the homozygous variant genotype for these 2 SNPs was observed among cases (4.1 and 3.2%, respectively) and not controls. Genotype associations were not modified by the presence or absence of DNA adducts in circulating lymphocytes. Three-loci haplotypes were not significantly associated with breast cancer risk.

Conclusions

These results should be confirmed in larger studies, but suggest that cigarette smoking may influence breast cancer risk through interaction with p53.

Goldman R, Shields PG (1998) Molecular epidemiology of breast cancer. In Vivo 12:43–48PubMed

Greenblatt MS, Bennett WP, Hollstein M, Harris CC (1994) Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 54:4855–4878PubMed

Bode AM, Dong Z (2004) Post-translational modification of p53 in tumorigenesis. Nat Rev Cancer 4:793–805PubMedCrossRef

Lioy PJ, Greenberg A (1990) Factors associated with human exposures to polycyclic aromatic hydrocarbons. Toxicol Ind Health 6:209–223PubMed

Conway K, Edmiston SN, Cui L, Drouin SS, Pang J, He M, Tse CK, Geradts J, Dressler L, Liu ET, Millikan R, Newman B (2002) Prevalence and spectrum of p53 mutations associated with smoking in breast cancer. Cancer Res 62:1987–1995PubMed

Li D, Zhang W, Sahin AA, Hittelman WN (1999) DNA adducts in normal tissue adjacent to breast cancer: a review. Cancer Detect Prev 23:454–462PubMedCrossRef

Martin FL, Venitt S, Carmichael PL, Crofton-Sleigh C, Stone EM, Cole KJ, Gusterson BA, Grover PL, Phillips DH (1997) DNA damage in breast epithelial cells: detection by the single-cell gel (comet) assay and induction by human mammary lipid extracts. Carcinogenesis 18:2299–2305PubMedCrossRef

Terry PD, Rohan TE (2002) Cigarette smoking and the risk of breast cancer in women: a review of the literature. Cancer Epidemiol Biomarkers Prev 11:953–971PubMed

Rundle A, Tang D, Hibshoosh H, Estabrook A, Schnabel F, Cao W, Grumet S, Perera FP (2000) The relationship between genetic damage from polycyclic aromatic hydrocarbons in breast tissue and breast cancer. Carcinogenesis 21:1281–1289PubMedCrossRef

10.

Gammon MD, Santella RM, Neugut AI, Eng SM, Teitelbaum SL, Paykin A, Levin B, Terry MB, Young TL, Wang LW, Wang Q, Britton JA, Wolff MS, Stellman SD, Hatch M, Kabat GC, Senie R, Garbowski G, Maffeo C, Montalvan P, Berkowitz G, Kemeny M, Citron M, Schnabel F, Schuss A, Hajdu S, Vinceguerra V (2002) Environmental toxins and breast cancer on Long Island. I. Polycyclic aromatic hydrocarbon DNA adducts. Cancer Epidemiol Biomarkers Prev 11:677–685PubMed

11.

Gammon MD, Sagiv SK, Eng SM, Shantakumar S, Gaudet MM, Teitelbaum SL, Britton JA, Terry MB, Wang LW, Wang Q, Stellman SD, Beyea J, Hatch M, Kabat GC, Wolff MS, Levin B, Neugut AI, Santella RM (2004) Polycyclic aromatic hydrocarbon-DNA adducts and breast cancer: a pooled analysis. Arch Environ Health 59:640–649PubMedCrossRef

12.

Easton D, Ford D, Peto J (1993) Inherited susceptibility to breast cancer. Cancer Surv 18:95–113PubMed

13.

Wu X, Zhao H, Amos CI, Shete S, Makan N, Hong WK, Kadlubar FF, Spitz MR (2002) p53 genotypes and haplotypes associated with lung cancer susceptibility and ethnicity. J Natl Cancer Inst 94:681–690PubMed

14.

Weston A, Pan CF, Ksieski HB, Wallenstein S, Berkowitz GS, Tartter PI, Bleiweiss IJ, Brower ST, Senie RT, Wolff MS (1997) p53 haplotype determination in breast cancer. Cancer Epidemiol Biomarkers Prev 6:105–112PubMed

15.

Kraft P, Cox DG, Paynter RA, Hunter D, De Vivo I (2005) Accounting for haplotype uncertainty in matched association studies: a comparison of simple and flexible techniques. Genet Epidemiol 28:261–272PubMedCrossRef

16.

Sjalander A, Birgander R, Hallmans G, Cajander S, Lenner P, Athlin L, Beckman G, Beckman L (1996) p53 polymorphisms and haplotypes in breast cancer. Carcinogenesis 17:1313–1316PubMedCrossRef

17.

Weston A, Wolff MS, Morabia A (1998) True extended haplotypes of p53: indicators of breast cancer risk. Cancer Genet Cytogenet 102:153–154PubMedCrossRef

18.

Gammon MD, Neugut AI, Santella RM, Teitelbaum SL, Britton JA, Terry MB, Eng SM, Wolff MS, Stellman SD, Kabat GC, Levin B, Bradlow HL, Hatch M, Beyea J, Camann D, Trent M, Senie RT, Garbowski GC, Maffeo C, Montalvan P, Berkowitz GS, Kemeny M, Citron M, Schnabe F, Schuss A, Hajdu S, Vincguerra V, Collman GW, Obrams GI (2002) The Long Island breast cancer study project: description of a multi-institutional collaboration to identify environmental risk factors for breast cancer. Breast Cancer Res Treat 74:235–254PubMedCrossRef

19.

Gammon MD, Eng SM, Teitelbaum SL, Britton JA, Kabat GC, Hatch M, Paykin AB, Neugut AI, Santella RM (2004) Environmental tobacco smoke and breast cancer incidence. Environ Res 96:176–185PubMedCrossRef

20.

Santella RM, Grinberg-Funes RA, Young TL, Dickey C, Singh VN, Wang LW, Perera FP (1992) Cigarette smoking related polycyclic aromatic hydrocarbon-DNA adducts in peripheral mononuclear cells. Carcinogenesis 13:2041–2045PubMedCrossRef

21.

Hosmer DW, Lemeshow S (1989) Applied Logistic Regression. John Wiley and Sons, Inc, New York

22.

Gemignani F, Moreno V, Landi S, Moullan N, Chabrier A, Gutierrez-Enriquez S, Hall J, Guino E, Peinado MA, Capella G, Canzian F (2004) A TP53 polymorphism is associated with increased risk of colorectal cancer and with reduced levels of TP53 mRNA. Oncogene 23:1954–1956PubMedCrossRef

23.

Sjalander A, Birgander R, Kivela A, Beckman G (1995) p53 polymorphisms and haplotypes in different ethnic groups. Hum Hered 45:144–149PubMed

24.

Mabrouk I, Baccouche S, El-Abed R, Mokdad-Gargouri R, Mosbah A, Said S, Daoud J, Frikha M, Jlidi R, Gargouri A (2003) No evidence of correlation between p53 codon 72 polymorphism and risk of bladder or breast carcinoma in Tunisian patients. Annal NY Acad Sci 1010:764–770CrossRef

25.

Pietsch EC, Humbey O, Murphy ME (2006) Polymorphisms in the p53 pathway. Oncogene 25:1602–1611PubMedCrossRef

26.

Huang XE, Hamajima N, Katsuda N, Matsuo K, Hirose K, Mizutani M, Iwata H, Miura S, Xiang J, Tokudome S, Tajima K (2003) Association of p53 codon Arg72Pro and p73 G4C14-to-A4T14 at exon 2 genetic polymorphisms with the risk of Japanese breast cancer. Breast Cancer 10:307–311PubMedCrossRef

27.

Dumont P, Leu JI, Della Pietra AC 3rd, George DL, Murphy M (2003) The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 33:357–365PubMedCrossRef

28.

Epstein MP, Satten GA (2003) Inference on haplotype effects in case-control studies using unphased genotype data. Am J Hum Genet 73:1316–1329PubMedCrossRef

29.

Langerod A, Bukholm IR, Bregard A, Lonning PE, Andersen TI, Rognum TO, Meling GI, Lothe RA, Borresen-Dale AL (2002) The TP53 codon 72 polymorphism may affect the function of TP53 mutations in breast carcinomas but not in colorectal carcinomas. Cancer Epidemiol Biomarkers Prev 11:1684–1688PubMed

30.

Bhatti P, Sigurdson AJ, Wang SS, Chen J, Rothman N, Hartge P, Bergen AW, Landi MT (2005) Genetic variation and willingness to participate in epidemiologic research: data from three studies. Cancer Epidemiol Biomarkers Prev 14:2449–2453PubMedCrossRef

Title: Genetic variation of TP53, polycyclic aromatic hydrocarbon-related exposures, and breast cancer risk among women on Long Island, New York
Authors: Mia M. Gaudet
Marilie D. Gammon
Jeannette T. Bensen
Sharon K. Sagiv
Sumitra Shantakumar
Susan L. Teitelbaum
Sybil M. Eng
Alfred I. Neugut
Regina M. Santella
Publication date: 01-03-2008
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 1/2008
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-007-9573-0

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Objectives

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2008

Gestational diabetes and the risk of breast cancer among women in the Jerusalem Perinatal Study

Evaluation of radiolabeled bombesin analogs in animals

Cancer-specific targeting of a conditionally replicative adenovirus using mRNA translational control

Controversies in preservation of ovary function and fertility in patients with breast cancer

Lifetime cumulative number of menstrual cycles and serum sex hormone levels in postmenopausal women

A Phase 2 study of perifosine in advanced or metastatic breast cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer